JOP20210286A1 - جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr - Google Patents
جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitrInfo
- Publication number
- JOP20210286A1 JOP20210286A1 JOP/2021/0286A JOP20210286A JOP20210286A1 JO P20210286 A1 JOP20210286 A1 JO P20210286A1 JO P20210286 A JOP20210286 A JO P20210286A JO P20210286 A1 JOP20210286 A1 JO P20210286A1
- Authority
- JO
- Jordan
- Prior art keywords
- gitr
- monoclonal antibody
- binds specifically
- antibody
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2019112296A RU2734432C1 (ru) | 2019-04-23 | 2019-04-23 | Моноклональное антитело, которое специфически связывается с GITR |
| PCT/RU2020/050080 WO2020218951A2 (ru) | 2019-04-23 | 2020-04-23 | Моноклональное антитело, которое специфически связывается с gitr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210286A1 true JOP20210286A1 (ar) | 2021-10-24 |
Family
ID=69821666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0286A JOP20210286A1 (ar) | 2019-04-23 | 2021-10-24 | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US12410257B2 (enExample) |
| EP (1) | EP3964525A4 (enExample) |
| JP (1) | JP7695200B2 (enExample) |
| KR (1) | KR20220010501A (enExample) |
| CN (1) | CN110903392B (enExample) |
| AR (1) | AR118763A1 (enExample) |
| AU (1) | AU2020261207B2 (enExample) |
| BR (1) | BR112021021281A2 (enExample) |
| CA (1) | CA3137822A1 (enExample) |
| CL (1) | CL2021002792A1 (enExample) |
| CO (1) | CO2021014153A2 (enExample) |
| EA (1) | EA202192907A1 (enExample) |
| IL (1) | IL287531A (enExample) |
| JO (1) | JOP20210286A1 (enExample) |
| MA (2) | MA54969B2 (enExample) |
| MX (1) | MX2021012962A (enExample) |
| MY (1) | MY210018A (enExample) |
| PE (1) | PE20220144A1 (enExample) |
| PY (1) | PY2018606A (enExample) |
| RU (1) | RU2734432C1 (enExample) |
| TW (1) | TWI803718B (enExample) |
| UY (1) | UY38672A (enExample) |
| WO (1) | WO2020218951A2 (enExample) |
| ZA (1) | ZA202109374B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2724470C1 (ru) * | 2019-11-11 | 2020-06-23 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Применение cas9 белка из бактерии pasteurella pneumotropica для модификации геномной днк в клетках |
| CN111732658B (zh) * | 2020-06-28 | 2022-04-26 | 英诺湖医药(杭州)有限公司 | 一组gitr单克隆抗体及其医药用途 |
| CN112362876B (zh) * | 2020-08-06 | 2023-12-15 | 武汉天德生物科技有限公司 | 一种检测早期老年痴呆症的胶体金试纸条及其制备方法 |
| CN112540179B (zh) * | 2020-08-06 | 2023-07-07 | 武汉天德生物科技有限公司 | 一种测试ApoE4蛋白含量的ELISA试剂盒 |
| CN111763257B (zh) * | 2020-09-01 | 2020-12-15 | 北京百奥赛图基因生物技术有限公司 | 抗gitr抗体及其用途 |
| CN112646040B (zh) * | 2020-12-31 | 2022-03-25 | 中元汇吉生物技术股份有限公司 | 特异性结合人IgG4的蛋白及其应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| AU2004244626A1 (en) * | 2003-05-23 | 2004-12-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| WO2007005612A2 (en) | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
| IN2015DN02826A (enExample) * | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| LT3148579T (lt) | 2014-05-28 | 2021-05-25 | Agenus Inc. | Anti-gitr antikūnai ir jų panaudojimo būdai |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| SG11201705721WA (en) * | 2015-01-14 | 2017-08-30 | Brigham & Womens Hospital Inc | Treatment of cancer with anti-lap monoclonal antibodies |
| EP3365371B1 (en) | 2015-10-22 | 2025-10-08 | Ablynx NV | Gitr agonists |
| AU2016364895A1 (en) | 2015-12-02 | 2018-06-07 | Agenus Inc. | Anti-GITR antibodies and methods of use thereof |
| CA3027121A1 (en) | 2016-06-10 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Anti-gitr antibodies and uses thereof |
| US20190263919A1 (en) | 2016-07-01 | 2019-08-29 | Five Prime Therapeutics, Inc. | Combined anti tumor therapy with a gitr agonist and cpg |
| CA3033665A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| CA3042727A1 (en) * | 2016-11-19 | 2018-05-24 | Potenza Therapeutics, Inc. | Anti-gitr antigen-binding proteins and methods of use thereof |
| WO2018145075A1 (en) | 2017-02-06 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for augmenting antibody mediated receptor signaling |
| US11198735B2 (en) * | 2017-03-03 | 2021-12-14 | Rinat Neuroscience Corp. | Anti-GITR antibodies and methods of use thereof |
| TWI788340B (zh) * | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
-
2019
- 2019-04-23 RU RU2019112296A patent/RU2734432C1/ru active
- 2019-12-03 TW TW108144110A patent/TWI803718B/zh active
- 2019-12-03 CN CN201911222245.8A patent/CN110903392B/zh active Active
-
2020
- 2020-04-22 UY UY0001038672A patent/UY38672A/es active IP Right Grant
- 2020-04-23 WO PCT/RU2020/050080 patent/WO2020218951A2/ru not_active Ceased
- 2020-04-23 AR ARP200101146A patent/AR118763A1/es unknown
- 2020-04-23 JP JP2021563239A patent/JP7695200B2/ja active Active
- 2020-04-23 MX MX2021012962A patent/MX2021012962A/es unknown
- 2020-04-23 MY MYPI2021006363A patent/MY210018A/en unknown
- 2020-04-23 KR KR1020217038209A patent/KR20220010501A/ko active Pending
- 2020-04-23 US US17/605,933 patent/US12410257B2/en active Active
- 2020-04-23 EP EP20794288.9A patent/EP3964525A4/en active Pending
- 2020-04-23 BR BR112021021281A patent/BR112021021281A2/pt unknown
- 2020-04-23 AU AU2020261207A patent/AU2020261207B2/en active Active
- 2020-04-23 CA CA3137822A patent/CA3137822A1/en active Pending
- 2020-04-23 MA MA54969A patent/MA54969B2/fr unknown
- 2020-04-23 PE PE2021001765A patent/PE20220144A1/es unknown
- 2020-04-23 EA EA202192907A patent/EA202192907A1/ru unknown
- 2020-05-06 PY PY202002018606A patent/PY2018606A/es unknown
- 2020-06-30 MA MA55390A patent/MA55390B1/fr unknown
-
2021
- 2021-10-22 CL CL2021002792A patent/CL2021002792A1/es unknown
- 2021-10-22 CO CONC2021/0014153A patent/CO2021014153A2/es unknown
- 2021-10-24 JO JOP/2021/0286A patent/JOP20210286A1/ar unknown
- 2021-10-24 IL IL287531A patent/IL287531A/en unknown
- 2021-11-22 ZA ZA2021/09374A patent/ZA202109374B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA54969A1 (fr) | 2022-08-31 |
| MY210018A (en) | 2025-08-21 |
| CA3137822A1 (en) | 2020-10-29 |
| WO2020218951A3 (ru) | 2020-12-24 |
| AU2020261207A1 (en) | 2021-12-23 |
| UY38672A (es) | 2020-10-30 |
| MX2021012962A (es) | 2021-12-15 |
| EA202192907A1 (ru) | 2022-01-25 |
| PY2018606A (es) | 2023-09-15 |
| MA54969B2 (fr) | 2025-10-31 |
| TWI803718B (zh) | 2023-06-01 |
| PE20220144A1 (es) | 2022-01-27 |
| ZA202109374B (en) | 2022-12-21 |
| CN110903392A (zh) | 2020-03-24 |
| TW202100554A (zh) | 2021-01-01 |
| JP7695200B2 (ja) | 2025-06-18 |
| CN110903392B (zh) | 2024-02-13 |
| AR118763A1 (es) | 2021-10-27 |
| CL2021002792A1 (es) | 2022-06-24 |
| MA55390B1 (fr) | 2022-10-31 |
| EP3964525A4 (en) | 2022-12-28 |
| BR112021021281A2 (pt) | 2022-03-08 |
| WO2020218951A2 (ru) | 2020-10-29 |
| AU2020261207B2 (en) | 2026-08-06 |
| KR20220010501A (ko) | 2022-01-25 |
| IL287531A (en) | 2021-12-01 |
| CO2021014153A2 (es) | 2021-10-29 |
| MA55390A1 (fr) | 2022-05-31 |
| EP3964525A2 (en) | 2022-03-09 |
| RU2734432C1 (ru) | 2020-10-16 |
| US12410257B2 (en) | 2025-09-09 |
| US20220213209A1 (en) | 2022-07-07 |
| JP2022532991A (ja) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200078B1 (ar) | أجسام مضادة خاصة بـ cd47 وpd-l1 | |
| WO2020218951A3 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
| MX2024010985A (es) | Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control. | |
| PH12019502298A1 (en) | Monoclonal antibody to pd-l1 | |
| PH12017501190B1 (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| JOP20220255A1 (ar) | أجسام tau المضادة لـ phf المضاد واستخداماتها | |
| SA522440646B1 (ar) | أجسام مضادة ترتبط بـ siglec15 واستخداماتها | |
| JOP20210100A1 (ar) | جسم مضاد أحادي النسيلة يرتبط على وجه التحديد بـ cd20 | |
| PE20181199A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
| PH12020550218A1 (en) | MONOCLONAL ANTIBODY TO IL-5Ra | |
| HK20008640A1 (en) | Monoclonal antibody that specifically binds to gitr | |
| BR112022006330A2 (pt) | Anticorpos anti-kir3dl3 e usos dos mesmos | |
| TH1901000154A (th) | แอนติบอดีต้าน pd-1, วิธีการผลิตและวิธีการใช้ของสิ่งดังกล่าว | |
| WO2021012092A9 (en) | A novel anti-pd-l1 antibody and use thereof | |
| UY37915A (es) | Anticuerpos específicos para cd47 y pd-l1 | |
| EA202090583A1 (ru) | Композиции на основе антител против a33 и способы их применения в радиоиммунотерапии | |
| TH1901005699A (th) | แอนติ-phf-เทาแอนติบอดีและการใช้สิ่งดังกล่าว | |
| TH1601002553A (th) | การผลิตเฮทเทอโร-ไดเมอริก อิมมูโนโกลบูลิน ซึ่งกำหนดเป้าหมายซ้ำต่อ t เซลล์ |